Log In
BCIQ
Print this Print this
 

poziotinib (HM781-36B, NOV12010)

  Manage Alerts
Collapse Summary General Information
Company Hanmi Pharmaceutical Co. Ltd.
DescriptionOral pan-HER inhibitor
Molecular Target Epidermal growth factor receptor 1 (EGFR1) (HER1) (ErbB1) ; Epidermal growth factor receptor 2 (HER2) (EGFR2) (ErbB2) (neu)
Mechanism of ActionEpidermal growth factor (EGF) receptor 2 (HER2) (ErbB2) (neu) inhibitor; Epidermal growth factor (EGF) receptor 1 (HER1) (ErbB1) inhibitor; Epidermal growth factor (EGF) receptor 4 (HER4) (ErbB4) inhibitor
Therapeutic ModalitySmall molecule

 Product Details
Disease CategoryStandard IndicationIndication DetailsPartnersMilestonesLatest Stage of DevelopmentRegulatory Designation
 Archive Items are loading loading
Collapse Summary Deals Information
Total Number of DealsTotal Deal ValueTotal Upfront CashTotal Milestone Payments

2

$20.0M

0

$358.0M


 Deals Details
DateCompanies InvolvedDeal HeadlineTotal Deal ValueTotal Upfront CashTotal Milestone

03/04/2015

Undisclosed

Undisclosed

$358.0M

08/26/2014

$20.0M

Undisclosed

Undisclosed

Get a free BioCentury trial today